Volume 96, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The Neglected Tropical Disease Voucher Program is a Congressionally-mandated program intended to promote approval of products for tropical diseases because it provides spectacular financial compensation consequent to FDA approval of a priority product. Three drug approvals–artemether/lumifantrine for malaria, bedaquiline for multidrug resistant tuberculosis, miltefosine for leishmaniasis–have received Tropical Disease Vouchers to date. We give our view of the type of products that might qualify for a Tropical Disease Voucher, financial considerations in venturing capital to support product development, clinical ramifications of a successful product approval, and an overall evaluation of the Program.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Food and Drug Administration (FDA), 2008. Guidance for Industry: Tropical Disease Priority Review Vouchers. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM080599.pdf. [Google Scholar]
  2. Ridley DB, Grabowski HG, Moe JL, , 2006. Developing drugs for developing countries. Health Aff 25: 313324.[Crossref] [Google Scholar]
  3. Berman J, , 2015. Miltefosine, and FDA-approved drug for the ‘orphan disease’, leishmaniasis. Expert Opin Orphan Drugs 3: 727735.[Crossref] [Google Scholar]
  4. Varond AJ, , 2015. Priority Review Voucher Updates: Valuation, Eligibility, Reauthorization. Available at: http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/08/priority-review-voucher-updates-valuation-eligibility-reauthorization.html. [Google Scholar]
  5. Food and Drug Administration (FDA)/Center for Drug Evaluation and Research (CDER), 2013. Review Designation Policy: MAPP 6020.3 Rev. 2. Available at: https://www.google.com/#q=ucm082000. [Google Scholar]
  6. Food and Drug Administration (FDA), 2013. Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics. Available at: https://www.google.com/#q=fda+expedited+programs. [Google Scholar]
  7. Ridley DB, Régnier SA, , 2016. The commercial value for priority review vouchers. Health Aff 35: 776783.[Crossref] [Google Scholar]
  8. Kesselheim AS, Maggs LR, Sarpatwari A, , 2015. Experience with the priority review voucher program for drug development. JAMA 314: 16871688.[Crossref] [Google Scholar]
  9. Food and Drug Administration (FDA), 2009. Coartem Approval Letter. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000TOC.cfm. [Google Scholar]
  10. Food and Drug Administration (FDA), 2012. Bedaquiline Approval Letter. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000TOC.cfm. [Google Scholar]
  11. Food and Drug Administration (FDA), 2014. Miltefosine Approval Letter. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000TOC.cfm. [Google Scholar]
  12. Congress.gov, 2014. S.2917: Adding Ebola to the FDA Priority Review Voucher Program Act. Available at: https://www.congress.gov/bill/113th-congress/senate-bill/2917. [Google Scholar]

Data & Media loading...

  • Received : 08 Feb 2016
  • Accepted : 01 Aug 2016
  • Published online : 11 Jan 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error